Want to see SE:SUS full AI Analyst Report?
SUS Stock Chart & Stats
kr30.84
kr0.26(0.80%)
At close: 4:00 PM EDT
kr30.84
kr0.26(0.80%)
Day’s Range― - ―
52-Week Rangekr23.70 - kr102.80
Previous CloseN/A
Volume30.20K
Average Volume (3M)1.61M
Market Cap
kr2.59B
Enterprise Valuekr964.04
Total Cash (Recent Filing)kr658.39M
Total Debt (Recent Filing)kr2.86M
Price to Earnings (P/E)28.5
Beta0.68
Next Earnings
Nov 12, 2026EPS Estimate
0.68Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.83
Shares Outstanding51,026,237
10 Day Avg. Volume583,608
30 Day Avg. Volume1,614,194
Financial Highlights & Ratios
PEG Ratio-0.50
Price to Book (P/B)0.39
Price to Sales (P/S)1.67
P/FCF Ratio24.35
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
kr45.00Price Target Upside45.91% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)2.06
Revenue Forecast (FY)kr986.87M
Bulls Say, Bears Say
Bulls Say
Strong Growth And Recurring License MomentumRapid license growth and rising mix support a more scalable revenue model than hardware alone. Broader adoption across robotics customers can deepen recurring content relationships and improve revenue quality over the next several quarters.
Margin Delivery And Operational ImprovementsAchieving the target margin while growing indicates operating discipline and potential scalability. Pricing, product mix, and lower sales and administrative cost ratios could help sustain profitability as simulator volumes and license activity expand.
Debt-free Balance Sheet And Positive Cash GenerationA debt-free balance sheet gives Surgical Science flexibility to fund production capacity, product development, and strategic initiatives without material financing pressure. Positive operating cash flow also supports resilience through uneven project timing.
Bears Say
Profitability And Growth Have Cooled From Prior PeaksThe longer-term slowdown in growth and margin compression indicate that recent performance has not fully preserved earlier economics. Sustained recovery depends on converting operational improvements and product expansion into durable earnings growth.
Structural Weakness In ChinaSupport for domestic Chinese manufacturers represents a structural competitive and market-access challenge rather than a temporary demand dip. It may limit regional growth, require additional investment, and reduce the contribution from an important healthcare market.
Lumpy Revenue And Execution VisibilityLong sales cycles, project-based development work, and uncertain customer-related revenue changes can make results difficult to forecast. This volatility may complicate capacity planning and create periods where reported growth and cash conversion diverge.
Surgical Science Sweden AB News
SUS FAQ
What was Surgical Science Sweden AB’s price range in the past 12 months?
Surgical Science Sweden AB lowest stock price was kr23.70 and its highest was kr102.80 in the past 12 months.
What is Surgical Science Sweden AB’s market cap?
Surgical Science Sweden AB’s market cap is kr2.59B.
When is Surgical Science Sweden AB’s upcoming earnings report date?
Surgical Science Sweden AB’s upcoming earnings report date is Nov 12, 2026 which is in 77 days.
How were Surgical Science Sweden AB’s earnings last quarter?
Surgical Science Sweden AB released its earnings results on Aug 19, 2026. The company reported kr0.41 earnings per share for the quarter, missing the consensus estimate of kr0.46 by -kr0.05.
Is Surgical Science Sweden AB overvalued?
According to Wall Street analysts Surgical Science Sweden AB’s price is currently Undervalued.
Does Surgical Science Sweden AB pay dividends?
Surgical Science Sweden AB does not currently pay dividends.
What is Surgical Science Sweden AB’s EPS estimate?
Surgical Science Sweden AB’s EPS estimate is 0.68.
How many shares outstanding does Surgical Science Sweden AB have?
Surgical Science Sweden AB has 51,026,237 shares outstanding.
What happened to Surgical Science Sweden AB’s price movement after its last earnings report?
Surgical Science Sweden AB reported an EPS of kr0.41 in its last earnings report, missing expectations of kr0.46. Following the earnings report the stock price went up 24.706%.
Which hedge fund is a major shareholder of Surgical Science Sweden AB?
Currently, no hedge funds are holding shares in SE:SUS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Surgical Science Sweden AB
Surgical Science Sweden AB (publ) specializes in the creation and distribution of virtual reality (VR) simulation platforms designed for evidence-backed training in laparoscopic and endoscopic procedures. Among its key offerings is the LapSim training system, which includes LapSim ST, tailored for educating surgical technologists and assistants, as well as LapSim essence, a compact and readily deployable VR simulator. The company's product portfolio further extends to the EndoSim system, a dedicated endoscopy simulator for comprehensive medical training. It also features TeamSim, an innovative platform fostering inter-professional education by integrating surgical simulation with real-world team dynamics. Additionally, they provide the Simball Box, which delivers velocity feedback alongside instructional task videos demonstrating optimal techniques, alongside their well-known Simbionix and robotic surgery simulators. Established in 1999, Surgical Science AB maintains its headquarters in Gothenburg, Sweden.
SUS Stock 12 Month Forecast
Average Price Target
kr45.00
▲(45.91% Upside)
Technical Analysis
RaySearch Laboratories AB
―
Stille AB
―
OssDsign AB
―
FluoGuide A/S
―
Physitrack Limited
―




